Artal Group’s Denali Therapeutics DNLI Stock Holding History

Artal Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-502,899	Closed	-$11.7M	–	28
2024 Q2	$11.7M	Hold	502,899	–	–	0.3%	37
2024 Q1	$10.3M	Sell	502,899 -300,000	-37%	-$5.64M	0.26%	45
2023 Q4	$17.2M	Hold	802,899	–	–	0.57%	25
2023 Q3	$16.6M	Hold	802,899	–	–	0.71%	23
2023 Q2	$23.7M	Hold	802,899	–	–	0.73%	19
2023 Q1	$18.5M	Buy	802,899 +2,899	+0.4%	+$79.8K	1.1%	23
2022 Q4	$22.2M	Buy	800,000 +200,000	+33%	+$5.95M	1.24%	25
2022 Q3	$18.4M	Hold	600,000	–	–	0.79%	29
2022 Q2	$17.7M	Hold	600,000	–	–	0.94%	29
2022 Q1	$19.3M	Hold	600,000	–	–	0.81%	30
2021 Q4	$26.8M	Buy	600,000 +100,000	+20%	+$4.74M	0.73%	34
2021 Q3	$25.2M	Hold	500,000	–	–	0.56%	44
2021 Q2	$39.2M	Hold	500,000	–	–	0.8%	27
2021 Q1	$28.6M	Buy	500,000 +100,000	+25%	+$6.69M	0.5%	47
2020 Q4	$33.5M	Hold	400,000	–	–	0.72%	38
2020 Q3	$14.3M	Sell	400,000 -50,000	-11%	-$1.51M	0.35%	63
2020 Q2	$10.9M	Sell	450,000 -50,000	-10%	-$1.18M	0.3%	67
2020 Q1	$8.76M	Buy	500,000 +100,000	+25%	+$2.09M	0.37%	52
2019 Q4	$6.97M	Hold	400,000	–	–	0.27%	63
2019 Q3	$6.13M	Hold	400,000	–	–	0.25%	67
2019 Q2	$8.3M	Hold	400,000	–	–	0.34%	58
2019 Q1	$9.29M	Sell	400,000 -100,000	-20%	-$2.09M	0.38%	55
2018 Q4	$10.3M	Hold	500,000	–	–	0.38%	42
2018 Q3	$10.9M	Hold	500,000	–	–	0.28%	50
2018 Q2	$7.63M	Buy	500,000 +50,000	+11%	+$942K	0.16%	56
2018 Q1	$8.86M	Sell	450,000 -50,000	-10%	-$1.03M	0.11%	52
2017 Q4	$7.82M	Buy	+500,000	New	+$8.99M	0.12%	53

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Artal Group's DNLI Position: Q3 2024 in Review

Artal Group sold out of Denali Therapeutics (DNLI) in Q3 2024, closing a stake of 502,899 shares — an estimated $11.7M sold.

Artal Group first reported a position in DNLI in Q4 2017 and held it in 27 quarters. The position peaked at $39.2M in Q2 2021. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

Artal Group reported no remaining Denali Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 502,899 Denali Therapeutics shares in Q3 2024, an estimated $11.7M.
Artal Group first reported a position in Denali Therapeutics in Q4 2017 and held it in 27 quarters.
Artal Group's Denali Therapeutics position peaked at $39.2M in Q2 2021.
217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.